Gilead Sciences, Inc. (GILD)
GILD Stock Slips as CVS Health Excludes New HIV Drug Yeztugo
Gilead shares slip after CVS refused to add its new HIV drug, Yeztugo, while its Kite unit struck a $350 million deal with Interius BioTherapeutics.
From Stagnation To Surge: Gilead Sciences Is Entering Its Next Growth Wave
Gilead Sciences remains a long-term Buy due to solid quarterly results, raised guidance, and continued strength in its HIV portfolio, especially Biktarvy. The recent launch of Yeztugo and a robust HIV pipeline support accelerating long-term growth, with analysts raising EPS estimates and management optimistic on margins. Despite recent gains, Gilead is still undervalued based on free cash flow and intrinsic value calculations, offering further upside potential for investors.
GILD Stock Up 7% Post Q2 Earnings: Should You Buy Now or Wait?
Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP launch Yeztugo.
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
GILD Stock Rises on Q2 Earnings and Sales Beat, '25 View Up
GILD tops Q2 earnings, raises 2025 guidance as HIV drugs Biktarvy and Descovy drive revenue growth.
Gilead Sciences, Inc. (GILD) Q2 2025 Earnings Call Transcript
Gilead Sciences, Inc. (NASDAQ:GILD ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Andrew D. Dickinson - Chief Financial Officer Daniel P.
Gilead (GILD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Gilead (GILD) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Gilead Sciences Q2: The New Drug That Could Change Everything
Gilead Sciences, Inc.'s HIV franchise, led by Biktarvy, ensures stable cash flows through 2033, providing long-term visibility and a strong competitive advantage. The launch of Yeztugo, a biannual PrEP injection, could significantly expand Gilead's market share and drive future revenue growth. Valuation remains attractive: GILD trades below peer multiples, boasts robust margins, and offers a sector-leading dividend yield above 2.8%.
Gilead Sciences (GILD) Tops Q2 Earnings and Revenue Estimates
Gilead Sciences (GILD) came out with quarterly earnings of $2.01 per share, beating the Zacks Consensus Estimate of $1.95 per share. This compares to earnings of $2.01 per share a year ago.
Seeking Clues to Gilead (GILD) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of Gilead (GILD) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
GILD Likely to Beat on Q2 Earnings: Buy, Sell or Hold the Stock?
GILD eyes Q2 gains as demand for HIV drugs holds strong despite pricing pressures and cell therapy headwinds. We recommend investors to wait and watch for now.
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Should You Buy?
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
